Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.56 |
| ▸ | PREP | P48147 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9202585 | 1.00 | ACE2 (0.56) | ACE2PREPSMN1; SMN2CYP2C19RAB9A | |
| SCHEMBL9202571 | 1.00 | ACE2 (0.56) | ACE2PREPSMN1; SMN2CYP2C19RAB9A | |
| Hydrochloric Acid SCHEMBL10613441 | 0.99 | ACE2 (0.55) | ACE2PREPSMN1; SMN2CYP2C19RAB9A | |
| Hydrochloric Acid SCHEMBL30452756 | 0.99 | ACE2 (0.55) | ACE2PREPSMN1; SMN2CYP2C19RAB9A | |
| SCHEMBL5305188 | 0.96 | SMN1; SMN2 (0.52) | ACE2PREPSMN1; SMN2CYP2C19RAB9A | |
| SCHEMBL13961188 | 0.96 | SMN1; SMN2 (0.52) | ACE2PREPSMN1; SMN2CYP2C19RAB9A | |
| Hydrochloric Acid SCHEMBL26120340 | 0.95 | SMN1; SMN2 (0.51) | ACE2PREPSMN1; SMN2CYP2C19RAB9A | |
| SCHEMBL25762544 | 0.92 | SMN1; SMN2 (0.56) | ACE2PREPSMN1; SMN2CYP2C19RAB9A | |
| SCHEMBL5267939 | 0.88 | SPHK2 (0.58) | ACE2PREPSMN1; SMN2CYP2C19RAB9A | |
| SCHEMBL4602602 | 0.88 | SPHK2 (0.58) | ACE2PREPSMN1; SMN2CYP2C19RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4440700-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | Gilead Sciences, Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| US-12084467-B2 | Therapeutic compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| CN-118355020-A | Therapeutic compounds for HIV virus infection | 吉利德科学公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20230203071-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230203071-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230203071-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023102529-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-9605296-B2 | Fluorogenic peptidase substrate | ECOLE NORMALE SUPERIEURE DE LYON (FR) | 2017-03-28 | — | — | US | disclosed |
| US-20140234887-A1 | FLUOROGENIC PEPTIDASE SUBSTRATE | CENTRE NATIONAL DE LA RECHERCHE SCIENTFIQUE (FR) | 2014-08-21 | — | — | US | disclosed |
| US-7968734-B2 | Organocatalysts and methods of use in chemical synthesis | STC.UNM (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968734-B2 | Organocatalysts and methods of use in chemical synthesis | STC.UNM (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968734-B2 | Organocatalysts and methods of use in chemical synthesis | STC.UNM (US) | 2011-06-28 | — | — | US | disclosed |
| US-20070244328-A1 | Organocatalysts and Methods of Use in Chemical Synthesis | STC.UNM (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244328-A1 | Organocatalysts and Methods of Use in Chemical Synthesis | STC.UNM (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244328-A1 | Organocatalysts and Methods of Use in Chemical Synthesis | STC.UNM (US) | 2007-10-18 | — | — | US | disclosed |
| EP-0421441-B1 | Pantothenic acid derivatives | FUJIREBIO KK (JP) | 1995-01-25 | — | — | EP | disclosed |
| US-5120738-A | Cardiovascular disorders | FUJIREBIO INC. (JP) | 1992-06-09 | — | — | US | disclosed |
| EP-0421441-A2 | Pantothenic acid derivatives | FUJIREBIO INC. (JP) | 1991-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244328-A1 | Organocatalysts and Methods of Use in Chemical Synthesis | SCO2, CBR1, CBR3 | ACE2 1756/4885PREP 4006/4885SMN1; SMN2 3982/4885 |
| US-12084467-B2 | Therapeutic compounds for HIV virus infection | HAVCR2, MAVS, CD4 | ACE2 732/4885PREP 901/4885SMN1; SMN2 3008/4885 |
| US-20230203071-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | HAVCR2, MAVS, CD4 | ACE2 732/4885PREP 901/4885SMN1; SMN2 3008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.